Semaphorins in angiogenesis and tumor progression

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 1, 2012, Pages

  Neufeld, Gera ^a   Sabag, Adi D ^a   Rabinovicz, Noa ^a   Kessler, Ofra ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 2; MATRIX METALLOPROTEINASE 14; NEUROPILIN 1; NEUROPILIN 2; PLATELET DERIVED GROWTH FACTOR B; PLEXIN; PROTEIN P53; SEMAPHORIN; SEMAPHORIN 3A; SEMAPHORIN 3B; SEMAPHORIN 3F; SEMAPHORIN 4A; SEMAPHORIN 4D; SEMAPHORIN 4F; SEMAPHORIN 5; SEMAPHORIN 5A; SEMAPHORIN 5B; SEMAPHORIN 6A; SEMAPHORIN 6D; SEMAPHORIN 7A; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; IMMUNOPHILIN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TUMOR GROWTH; DISEASE COURSE; GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNOPHILINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SEMAPHORINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84865134317     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006718     Document Type: Article

References (122)

1. Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA. 2008. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111: 2674-2680.
2. Antipenko A, Himanen JP, van Leyen K, Nardi-Dei V, Lesniak J, Barton WA, Rajashankar KR, Lu M, Hoemme C, Puschel AW, et al. 2003. Structure of the semaphorin-3a receptor binding module. Neuron 39: 589-598.
3. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, Mortara K, BowmanKK, Elliott JM, Desmarais W, et al. 2007. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 26: 4902-4912.
4. Artigiani S, Conrotto P, Fazzari P, Gilestro GF, Barberis D, Giordano S, Comoglio PM, Tamagnone L. 2004. Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep 5: 710-714.
5. Ausprunk DH, Knighton DR, Folkman J. 1975. Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am J Pathol 79: 597-628.
6. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, Mercurio AM. 2003. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63: 5230-5233.
7. Bagci T, Wu JK, Pfannl R, Ilag LL, Jay DG. 2009. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 28: 3537-3550.
8. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. 2004. Class IV semaphorins promote angiogenesis by stimulating rho-initiated pathways through Plexin-B. Cancer Res 64: 5212-5224.
9. Basile JR, Afkhami T, Gutkind JS. 2005. Semaphorin 4D/Plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol Cell Biol 25: 6889-6898.
10. Basile JR, Castilho RM, Williams VP, Gutkind JS. 2006. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci 103: 9017-9022.
11. Basile JR, Holmbeck K, Bugge TH, Gutkind JS. 2007a. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem 282: 6899-6905.
12. Basile JR, Gavard J, Gutkind JS. 2007b. Plexin-B1 utilizes rhoa and rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem 282: 34888-34895.
13. Bassi DE, Fu J, Lopez de CR, Klein-Szanto AJ. 2005. Proprotein convertases: "Master switches" in the regulation of tumor growth and progression. Mol Carcinog 44: 151-161.
14. Bates D, Taylor GI, Minichiello J, Farlie P, Cichowitz A, Watson N, Klagsbrun M, Mamluk R, Newgreen DF. 2003. Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. Dev Biol 255: 77-98.
15. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, KlagsbrunM. 2004. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114: 1260-1271.
16. Beuten J, Garcia D, Brand TC, He X, Balic I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson IM, et al. 2009. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J Urol 182: 1614-1620.
17. Campioni M, Ambrogi V, Pompeo E, Citro G, Castelli M, Spugnini EP, Gatti A, Cardelli P, Lorenzon L, Baldi A, et al. 2008. Identification of genes down-regulated during lung cancer progression: A cDNA array study. J Exp Clin Cancer Res 27: 38.
18. Casazza A, Fu X, Johansson I, Capparuccia L, Andersson F, Giustacchini A, Squadrito ML, Venneri MA, Mazzone M, Larsson E, et al. 2011. Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol 31: 741-749.
19. Castro-Rivera E, Ran S, Thorpe P, Minna JD. 2004. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci 101: 11432-11437.
20. Castro-Rivera E, Ran S, Brekken RA, Minna JD. 2008. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res 68: 8295-8303.
21. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A. 2009. The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-κB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer Res 69: 1485-1493.
22. Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, et al. 2010. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 120: 2684-2698.
23. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. 1997. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19: 547-559.
24. Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L, Guldberg P, Lukanidin E. 2005. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res 65: 6167-6177.
25. Clarhaut J, Gemmill RM, Potiron VA, it-Si-Ali S, Imbert J, Drabkin HA, Roche J. 2009. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia 11: 157-166.
26. Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M. 2010. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res 70: 3823-3832.
27. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. 2004. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 5131-5137.
28. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, Bussolino F, Giordano S. 2005. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105: 4321-4329.
29. Dhanabal M, Wu F, Alvarez E, McQueeney KD, Jeffers M, Macdougall J, BoldogFL, Hackett C, Shenoy S, Khramtsov N, et al. 2005. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer Biol Ther 4: 659-668.
30. Drenberg CD, Livingston S, Chen R, Kruk PA, Nicosia SV. 2009. Expression of Semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes, and secondary mullerian tissues. Obstet Gynecol Int 2009: 730739.
31. Fazzari P, Penachioni J, Gianola S, Rossi F, Eickholt BJ, Maina F, Alexopoulou L, Sottile A, Comoglio PM, Flavell RA, et al. 2007. PlexinB1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev Biol 7: 55.
32. Feiner L, Koppel AM, Kobayashi H, Raper JA. 1997. Secreted chick semaphorins bind recombinant neuropilin with similar affinities but bind different subsets of neurons in situ. Neuron 19: 539-545.
33. Feiner L, Webber AL, Brown CB, Lu MM, Jia L, Feinstein P, Mombaerts P, EpsteinJA, Raper JA. 2001. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development 128: 3061-3070.
34. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25: 581-611.
35. Fiore R, Rahim B, Christoffels VM, Moorman AF, Puschel AW. 2005. Inactivation of the sema5a gene results in embryonic lethality and defective remodeling of the cranial vascular system. Mol Cell Biol 25: 2310-2319.
36. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent. J Nat Cancer Inst 82: 4-7.
37. Franco M, Tamagnone L. 2008. Tyrosine phosphorylation in semaphorin signalling: Shifting into overdrive. EMBO Rep 9: 865-871.
38. Futamura M, Kamino H, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y, Arakawa H. 2007. Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21. 3, in p53-regulated tumor angiogenesis suppression. Cancer Res 67: 1451-1460.
39. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. 2002. The Semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4: 720-724.
40. Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi B-Z, Neufeld G. 1996. Selective binding of VEGF121 to one of the three VEGF receptors of vascular endothelial cells. J Biol Chem 271: 5519-5523.
41. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. 2000. Neuropilin-2 and Neuropilin-1 are receptors for 165-amino acid long form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145 amino acid form of VEGF. J Biol Chem 275: 18040-18045.
42. Goodman CS, Kolodkin AL, Luo Y, Pueschel AW, Raper JA. 1999. Unified nomenclature for the semaphorins collapsins. Cell 97: 551-552.
43. Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, JessellTM, Kolodkin AL, Ginty DD. 2005. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 307: 265-268.
44. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. 2006. The neuropilins and their roll in tumorigenesis and tumor progression. Cancer Lett 231: 1-11.
45. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. 2007. Semaphorin-3A and Semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 282: 26294-26305.
46. He Z, Tessier-Lavigne M. 1997. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90: 739-751.
47. He H, Yang T, Terman JR, Zhang X. 2009. Crystal structure of the plexin A3 intracellular region reveals an autoinhibited conformation through active site sequestration. Proc Natl Acad Sci 106: 15610-15615.
48. Herman JG, Meadows GG. 2007. Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30: 1231-1238.
49. Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T. 2006. Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol 29: 799-827.
50. Huang S, Mills L, Mian B, Tellez C, Mccarty M, Yang XD, Gudas JM, Bar-Eli M. 2002. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161: 125-134.
51. Hung RJ, Yazdani U, Yoon J, Wu H, Yang T, Gupta N, Huang Z, van Berkel WJ, Terman JR. 2010. Mical links semaphorins to F-actin disassembly. Nature 463: 823-827.
52. Janssen BJ, Robinson RA, Perez-Branguli F, Bell CH, Mitchell KJ, Siebold C, Jones EY. 2010. Structural basis of semaphorin-plexin signalling. Nature 467: 1118-1122.
53. Joseph D, Ho SM, Syed V. 2010. Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Mol Cancer Ther 9: 499-509.
54. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, BuelerH, Eichmann A, Kauppinen R, Kettunen MI, et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci 98: 12677-12682.
55. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G. 2004. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64: 1008-1015.
56. Kigel B, Varshavsky A, Kessler O, Neufeld G. 2008. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS ONE 3: e3287.
57. Klostermann A, Lohrum M, Adams RH, Puschel AW. 1998. The chemorepulsive activity of the axonal guidance signal semaphorin D requires dimerization. J Biol Chem 273: 7326-7331.
58. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. 1997. Neuropilin is a semaphorin III receptor. Cell 90: 753-762.
59. Kumanogoh A, Kikutani H. 2003. Roles of the semaphorin family in immune regulation. Adv Immunol 81: 173-198.
60. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, KaiserLR, Croce CM. 2003. Allelic Loss on Chromosome 3p21. 3 and promoter hypermethylation of semaphorin 3b in non-small cell lung cancer. Cancer Res 63: 3352-3355.
61. Kusy S., Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. 2005. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 7: 457-465.
62. Lazova R., Gould Rothberg BE, Rimm D, Scott G. 2009. The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol 31: 177-181.
63. Liu H., Juo ZS, Shim AH, Focia PJ, Chen X, Garcia KC, He X. 2010. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell 142: 749-761.
64. Love CA, Harlos K, Mavaddat N, Davis SJ, Stuart DI, Jones EY, Esnouf RM. 2003. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol 10: 843-848.
65. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC, et al. 2010. Identification of a novel biomarker SEMA5A for non-small cell lung carcinoma in non-smoking women. Cancer Epidemiol Biomarkers Prev 19: 2590-2597.
66. Luo Y, Raible D, Raper JA. 1993. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75: 217-227.
67. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, ErikssonU, Alitalo K. 1999. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 274: 21217-21222.
68. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. 2009. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119: 3356-3372.
69. Marsit CJ, Wiencke JK, Liu M, Kelsey KT. 2005. The race associated allele of semaphorin 3B (SEMA3B) T415I and its role in lung cancer in African-Americans and Latino-Americans. Carcinogenesis 26: 1446-1449.
70. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. 1999. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility. Functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146: 233-242.
71. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G. 1998. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273: 22272-22278.
72. Muller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, Buchler P, Giese T, Buchler MW, Offermanns S, et al. 2007. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer 121: 2421-2433.
73. Nair PN, McArdle L, Cornell J, Cohn SL, Stallings RL. 2007. High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genet Cytogenet 174: 100-110.
74. Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J. 2003. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia 5: 83-92.
75. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J. 2005. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits e-cadherin-mediated cell adhesion. Neoplasia 7: 180-189.
76. Negishi M, Oinuma I, Katoh H. 2005a. Plexins: Axon guidance and signal transduction. Cell Mol Life Sci 62: 1363-1371.
77. Negishi M, Oinuma I, Katoh H. 2005b. R-ras as a key player for signaling pathway of plexins. Mol Neurobiol 32: 217-222.
78. Neufeld G, Kessler O. 2008. The semaphorins: Versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8: 632-645.
79. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
80. Nogi T, Yasui N, Mihara E, Matsunaga Y, Noda M, Yamashita N, Toyofuku T, Uchiyama S, Goshima Y, Kumanogoh A, et al. 2010. Structural basis for semaphorin signalling through the plexin receptor. Nature 467: 1123-1127.
81. Oinuma I, Ishikawa Y, Katoh H, Negishi M. 2004. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 305: 862-865.
82. Parker MW, Hellman LM, Xu P, Fried MG, Vander Kooi CW. 2010. Furin processing of semaphorin 3f determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 49: 4068-4075.
83. Parrinello S, Noon LA, Harrisingh MC, Digby PW, Rosenberg LH, Cremona CA, Echave P, Flanagan AM, Parada LF, Lloyd AC. 2008. NF1 loss disrupts Schwann cell-axonal interactions: A novel role for semaphorin 4F. Genes Dev 22: 3335-3348.
84. Pasterkamp RJ, Dai HN, Terman JR, Wahlin KJ, Kim B, Bregman BS, Popovich PG, Kolodkin AL. 2006. MICAL flavoprotein monooxygenases: Expression during neural development and following spinal cord injuries in the rat. Mol Cell Neurosci 31: 52-69.
85. Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. 2007. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 67: 8708-8715.
86. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R, et al. 1996. Distinct 3p21. 3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289-1297.
87. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, MedicoE, Carmeliet P, Comoglio PM, Tamagnone L. 2008. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205: 1155-1171.
88. Roodink I, Kats G, van KL, Grunberg M, Maass C, Verrijp K, Raats J, Leenders W. 2008. Semaphorin 3E expression correlates inversely with plexin d1 during tumor progression. Am J Pathol 173: 1873-1881.
89. Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, Lele SM, Batra SK, Singh RK. 2010. High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer 127: 1373-1383.
90. Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, PalmbyTR, Yagi H, Zhang F, Randazzo PA, Li X, et al. 2010. Semaphorin 3E initiates anti-angiogenic signaling through Plexin-D1 by regulating Arf6 and R-Ras. Mol Cell Biol 30: 3086-3098.
91. Scott GA, McClelland LA, Fricke AF, Fender A. 2008. Plexin C1, A Receptor for Semaphorin 7A, Inactivates cofilin and is a potential tumor suppressor for melanoma progression. J Invest Dermatol 129: 954-963.
92. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, Minna JD. 1996. Human semaphorins A(V) and IV reside in the 3p21. 3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci 93: 4120-4125.
93. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, et al. 2003. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424: 391-397.
94. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, et al. 2008. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205: 1673-1685.
95. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
96. Strongin AY. 2010. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 1803: 133-141.
97. Suto F, Ito K, Uemura M, Shimizu M, Shinkawa Y, Sanbo M, Shinoda T, TsuboiM, Takashima S, Yagi T, et al. 2005. Plexin-a4 mediates axon-repulsive activities of both secreted and transmembrane semaphorins and plays roles in nerve fiber guidance. J Neurosci 25: 3628-3637.
98. Suto F, Tsuboi M, Kamiya H, Mizuno H, Kiyama Y, Komai S, Shimizu M, SanboM, Yagi T, Hiromi Y, et al. 2007. Interactions between Plexin-A2, Plexin-A4, and Semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. Neuron 53: 535-547.
99. Swiercz JM, Kuner R, Offermanns S. 2004. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J Cell Biol 165: 869-880.
100. Swiercz JM, Worzfeld T, Offermanns S. 2008. ERBB-2 and met reciprocally regulate cellular signaling via plexin-B1. J Biol Chem 283: 1893-1901.
101. Takagi S, Tsuji T, Amagai T, Takamatsu T, Fujisawa H. 1987. Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol 122: 90-100.
102. Takagi S, Hirata T, Agata K, Mochii M, Eguchi G, Fujisawa H. 1991. The A5 antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors. Neuron 7: 295-307.
103. Takahashi T, Strittmatter SM. 2001. PlexinA1 autoinhibition by the plexin sema domain. Neuron 29: 429-439.
104. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM. 1999. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99: 59-69.
105. Tamagnone L, Comoglio PM. 2004. To move or not to move? EMBO Rep 5: 356-361.
106. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, WinbergML, Goodman CS, Poo M, et al. 1999. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99: 71-80.
107. Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
108. Taniguchi M, Masuda T, Mikami Y, Kimura M, Yoshida T, Mishina M, Shimizu T. 2011. Identification and characterization of a novel zebrafish semaphorin. Neurosci Lett 488: 215-220.
109. Terman JR, Mao T, Pasterkamp RJ, Yu HH, Kolodkin AL. 2002. MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 109: 887-900.
110. Tischoff I, Markwarth A, Witzigmann H, Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR, Tannapfel A. 2005. Allele loss and epigenetic inactivation of 3p21. 3 in malignant liver tumors. Int J Cancer 115: 684-689.
111. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, LermanMI, Gazdar AF, Minna JD. 2001. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21. 3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci 98: 13954-13959.
112. Toyofuku T, Zhang H, Kumanogoh A, Takegahara N, Suto F, Kamei J, Aoki K, Yabuki M, Hori M, Fujisawa H, et al. 2004. Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev 18: 435-447.
113. Toyofuku T, Yoshida J, Sugimoto T, Zhang H, Kumanogoh A, Hori M, KikutaniH. 2005. FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci 8: 1712-1719.
114. Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, Hori M. 2007. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J 26: 1373-1384.
115. Vacca A, Scavelli C, Serini G, Di PG, Cirulli T, Merchionne F, Ribatti D, Bussolino F, Guidolin D, Piaggio G, et al. 2006. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood 108: 1661-1667.
116. Valente G, Nicotra G, Arrondini M, Castino R, Capparuccia L, Prat M, Kerim S, Tamagnone L, Isidoro C. 2009. Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression. Cell Oncol 31: 423-436.
117. Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G. 2008. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res 68: 6922-6931.
118. Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, Kerbacher K, van den BA, Veldhuis P, Buys CH, et al. 1996. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32: 39-48.
119. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, Naylor SL. 2002. Semaphorin 3F gene from human 3p21. 3 suppresses tumor formation in nude mice. Cancer Res 62: 2637-2643.
120. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del TR, Suchting S, Medvinsky A, et al. 2010. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 188: 115-130.
121. Zhao XY, Chen L, Xu Q, Li YH. 2006. Expression of semaphorin 6D in gastric carcinoma and its significance. World J Gastroenterol 12: 7388-7390.
122. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, et al. 2007. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci 104: 1621-1626.